Web of Science: 19 cites, Scopus: 20 cites, Google Scholar: cites,
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Felip, Enriqueta (Hospital Universitari Vall d'Hebron)
Keedy, Vicki (Vanderbilt University Medical Center)
Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia)
Shepherd, Frances A (University of Toronto)
Insa, Amelia (Hospital Clínic Universitari (València))
Brown, Holly (Merck & Co., Inc., Whitehouse Station)
Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station)
Sathyanarayanan, Sriram (Whitehouse Station, NJ USA)
Reilly, John F (Merck & Co., Inc., Whitehouse Station)
Mauro, David (Merck & Co., Inc., Whitehouse Station)
Hsu, Karl (Sanofi Aventis)
Yan, Li (Merck & Co., Inc., Whitehouse Station)
Universitat Autònoma de Barcelona

Data: 2014
Resum: We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). The phase I trial determined the recommended dose and safety of erlotinib plus dalotuzumab at 5 mg/kg or 10 mg/kg weekly in 20 patients. The phase II trial compared outcomes to erlotinib alone and erlotinib plus dalotuzumab at the mg/kg established in the phase I trial. Erlotinib at 150 mg plus dalotuzumab at 10 mg/kg was safe. The phase II trial included 37 patients in the erlotinib arm and 38 patients in the erlotinib plus dalotuzumab arm. Progression-free survival was 1. 6 versus 2. 5 months, overall survival was 10. 2 and 6. 6 months, and the objective response rate was 7. 9% and 2. 7%, respectively, with no significant differences between the two arms. Grade 3-5 adverse events occurred in 11 (28. 9%) versus 13 (35. 1%) patients, respectively. The most frequent adverse events were asthenia (36. 8% vs. 37. 8%), dehydration (5. 3% vs. 2. 7%), diarrhea (71% vs. 81. 1%), hyperglycemia (13. 1% vs. 18. 9%), and skin-related toxicities (92. 1% vs. 86. 4%). The addition of dalotuzumab to erlotinib did not improve efficacy outcome in patients with refractory advanced NSCLC.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: Non-small-cell lung cancer ; Epidermal growth factor receptor ; Insulin growth factor receptor ; Dalotuzumab ; Phase I/II trial
Publicat a: Experimental Hematology & Oncology, Vol. 3 (november 2014) , ISSN 2162-3619

DOI: 10.1186/2162-3619-3-26
PMID: 25414803


8 p, 455.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-01-29, darrera modificació el 2021-08-08



   Favorit i Compartir